ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
A Nanoparticle-Integrated Complete Manufacturing Pipeline of Chemically Engineered Exosomes.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Clinical translation of engineered exosomes, an emerging class of cell therapies, is hampered by challenges in each step of the manufacture flow, namely biogenesis, cargo loading, isolation, and storage. Here, we present a technology termed Tat-PNCAS-MIMS-MSC-Exo for manufacturing chemically engineered exosomes, with the above four steps being integrated by the use of the nanoparticle PNCAS-Tat (Tat peptide-conjugated protein-nanoparticle co-assembly supraparticle). This technology enables drastic improvements in all four steps of the manufacture flow of chemically engineered exosomes derived from mesenchymal stem cells (MSCs), a commonly-used cell type for cell therapies. The stimulation effect of exosome biogenesis by Tat peptide can be amplified by nanoparticle conjugation, a previously unknown nano-effect. The novel design of magnet setup MIMS (mobile internal magnetic separation) enables a unique capacity for scale-up of magnetic isolation, i.e., near-identical time for different scales to achieve near-complete isolation. This offers an effective solution to the long-standing problem of scale-up in applying magnetic isolation for biomanufacturing, which usually requires larger scales than bioanalytical applications. The manufacture process is robust, scalable, and economical. We conduct mechanistic studies of the nano-bio interactions, and demonstrate applications of the products in multiple disease models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.